ProteaBio Europe SAS, a leading developer of new technology, announced today that the company has concluded an exclusive, worldwide license agreement with George Washington University for commercial rights to a new technology that provides rapid identification of a broad range of chemicals and biomolecules.
“We foresee a broad range of applications in chemical and biological research, surgical pathology, clinical diagnostics, chemical and biological defense, forensics, agriculture, and many other fields. LAESI is a breakthrough technology of the first order”
Known as Laser Ablation Electrospray Ionization or "LAESI" mass spectrometry, the technology is capable of directly identifying proteins, peptides, lipids, and metabolites found in biological samples, including tissue, blood, urine and even single cells. Extremely rapid (less than 2 seconds per analysis), sensitive and quantitative, LAESI also provides 3 dimensional mapping of biomolecules through depth profiling and lateral imaging. Proteins and metabolites can be identified and localized in cell structures, tissues and fluids.
LAESI technology was invented and developed in the laboratory of Dr. Akos Vertes Ph.D., Professor of Chemistry, Professor of Biochemistry & Molecular Biology, and Founder and Co-Director of the W.M. Keck Institute for Proteomics Technology, at the Department of Chemistry, George Washington University.